Hepatitis C Management in Special Populations
Summary
- The AASLD/IDSA guidelines recommend that children with chronic HCV infection who are older than 3 years of age should receive treatment with DAA regimens, if available for the child’s age group[AASLD-IDSA HCV]
- Treatment of children 3-11 years of age with chronic HCV infection should be deferred until interferon-sparing regimens are available for their age group
- Ledipasvir/sofosbuvir and sofosbuvir plus ribavirin are the first direct-acting antivirals approved by the FDA for the treatment of HCV infection in patients 12-17 years of age
Action required
- Login now to access all of your entitled content
or - View additional options to gain access to this content